« Back to Record
Baselga, J., Bradbury, I., Eidtmann, H., Di Cosimo, S., de Azambuja, E., Aura, C. M., Gomez, H., Dinh, P., Fauria, K., van Dooren, V., Aktan, G., Goldhirsch, A., Chang, T.-W., Horváth, Z., Coccia-Portugal, M., Domont, J., Tseng, L.-M., Kunz, G., Sohn, J. H., Semiglazov, V., Lerzo, G., Palacova, M., Probachai, V., Pusztai, L., Untch, M., Gelber, R., Piccart-Gebhart, M., & NeoALTTO Study Team, (2012). Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet, 379(9816), 633-640. doi:10.1016/S0140-6736(11)61847-3
Citation APA
Permalink
Permalink
http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/144694



